RecruitingPhase 2NCT07070466

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Studying NON RARE IN EUROPE: Adenocarcinoma of stomach

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts General Hospital
Principal Investigator
Samuel Klempner, MD
Massachusetts General Hospital
Intervention
Ivonescimab(drug)
Enrollment
40 target
Eligibility
18 years · All sexes
Timeline
20252028

Study locations (2)

Collaborators

Summit Therapeutics

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07070466 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

← Back to all trials